Medium NAPLEX Oncology Pharmacology Practice Questions

Mastering oncology is a critical component of the NAPLEX exam, requiring a deep understanding of chemotherapy mechanisms, side effect management, and specialized dosing protocols. This guide provides Medium NAPLEX Oncology Pharmacology Practice Questions designed to simulate the complexity of the actual board exam while reinforcing clinical knowledge.

Concept Explanation

Oncology pharmacology involves the study and application of antineoplastic agents, including cytotoxic chemotherapy, targeted biological therapies, and hormonal treatments used to inhibit the growth of malignant cells. To excel in this area for the NAPLEX Prep, candidates must distinguish between cell-cycle specific agents (like antimetabolites and taxanes) and cell-cycle non-specific agents (like alkylating agents and anthracyclines). Beyond mechanisms, the exam heavily emphasizes "high-alert" toxicities such as the cardiotoxicity of doxorubicin, the nephrotoxicity of cisplatin, and the hemorrhagic cystitis associated with cyclophosphamide. Understanding the supportive care required for these treatments, such as using erythropoiesis-stimulating agents or antiemetic regimens, is essential for patient safety and therapeutic success.

Solved Examples

1. Example 1: Calculating Cumulative Dose
   A patient is receiving Doxorubicin as part of their AC regimen. If the patient has received 4 cycles of 60 $mg/m^2$ and has a Body Surface Area (BSA) of 1.8 $m^2$, what is the total cumulative dose received?
   
   1. Calculate dose per cycle: $60 \text{ mg/m}^2 \times 1.8 \text{ m}^2 = 108 \text{ mg}$.
   2. Multiply by number of cycles: $108 \text{ mg} \times 4 = 432 \text{ mg}$.
   3. The cumulative dose is 432 mg. (Note: This is approaching the lifetime limit of 450-550 $mg/m^2$).
2. Example 2: Carboplatin Dosing using the Calvert Formula
   Calculate the dose of Carboplatin for a patient with a target AUC of 5 and a GFR of 75 mL/min.
   
   1. Use the Calvert Formula: $\text{Dose (mg)} = \text{Target AUC} \times ( \text{GFR} + 25)$.
   2. Plug in the values: $5 \times (75 + 25)$.
   3. Calculate: $5 \times 100 = 500 \text{ mg}$.
3. Example 3: Extravasation Management
   A patient experiences extravasation during a Vincristine infusion. What is the appropriate immediate intervention?
   
   1. Identify the agent: Vincristine is a vinca alkaloid.
   2. Determine thermal requirement: Vinca alkaloids require warm compresses, unlike most other vesicants which require cold.
   3. Identify antidote: Hyaluronidase may be injected subcutaneously around the site.

Practice Questions

1. A 55-year-old male is starting treatment with Cisplatin for lung cancer. Which of the following laboratory parameters must be monitored most closely to prevent a dose-limiting toxicity?

2. A patient is prescribed Mesna (Mesnex) to be administered with high-dose Cyclophosphamide. What is the primary purpose of adding Mesna to this regimen?

3. Which of the following monoclonal antibodies requires screening for a KRAS mutation before initiation in patients with colorectal cancer?

4. A patient receiving Fluorouracil (5-FU) develops significant diarrhea and oral mucositis. Which pharmacogenetic deficiency might explain this increased sensitivity to 5-FU toxicity?

5. A pharmacist is reviewing a profile for a patient starting Tamoxifen. The patient is also taking Fluoxetine for depression. Why is this combination clinically significant?

6. Calculate the BSA for a patient who is 5 feet 10 inches tall and weighs 185 lbs using the Mosteller formula. (Formula: $\text{BSA (m}^2) = \sqrt{\frac{ \text{Height (cm)} \times \text{Weight (kg)}}{3600}}$). Refer to Medium NAPLEX Body Surface Area Practice Questions for more calculation help.

7. A patient with breast cancer is scheduled to receive Trastuzumab. Which baseline diagnostic test is mandatory before starting this therapy?

8. Which of the following medications is used specifically to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving myelosuppressive chemotherapy?

9. A patient is receiving Ifosfamide. Beside Mesna, what is the most important supportive care measure to prevent bladder toxicity?

10. Which class of chemotherapy agents is most associated with the development of delayed-onset peripheral neuropathy?

Answers & Explanations

1. Serum Creatinine/BUN: Cisplatin is highly nephrotoxic. Monitoring renal function and ensuring aggressive hydration is vital to prevent acute kidney injury. This is a common theme in NAPLEX Oncology Pharmacology Practice Questions with Answers.
2. Prevention of Hemorrhagic Cystitis: Cyclophosphamide and Ifosfamide produce a metabolite called acrolein, which irritates the bladder lining. Mesna binds to acrolein in the bladder to neutralize it.
3. Cetuximab (Erbitux): Cetuximab is an EGFR inhibitor. It is only effective in patients with "wild-type" (non-mutated) KRAS. If a KRAS mutation is present, the downstream signaling remains active despite EGFR inhibition.
4. DPD Deficiency: Dihydropyrimidine dehydrogenase (DPD) is the primary enzyme responsible for the metabolism of 5-FU. Patients with a deficiency are at high risk for severe, potentially fatal toxicities.
5. CYP2D6 Inhibition: Tamoxifen is a prodrug converted to its active metabolite, endoxifen, via CYP2D6. Fluoxetine is a strong CYP2D6 inhibitor and can decrease the efficacy of Tamoxifen.
6. 2.03 $m^2$:
   • Height: 70 inches $\times 2.54 = 177.8 \text{ cm}$.
   • Weight: 185 lbs $/ 2.2 = 84.1 \text{ kg}$.
   • Calculation: $\sqrt{\frac{177.8 \times 84.1}{3600}} = \sqrt{4.15} \approx 2.03 \text{ m}^2$.
7. Echocardiogram or MUGA scan: Trastuzumab (Herceptin) is associated with cardiotoxicity, specifically a decrease in Left Ventricular Ejection Fraction (LVEF). Baseline and periodic cardiac monitoring are required.
8. Filgrastim (Neupogen): Filgrastim is a Granulocyte Colony-Stimulating Factor (G-CSF) that stimulates the production of neutrophils in the bone marrow.
9. Aggressive Intravenous Hydration: Maintaining a high urine output (at least 2 liters per day) helps flush acrolein out of the bladder, complementing the action of Mesna.
10. Taxanes (e.g., Paclitaxel) or Vinca Alkaloids (e.g., Vincristine): These agents disrupt microtubule formation, which is essential for axonal transport in neurons, leading to peripheral neuropathy.

1. Which medication is the preferred treatment for chemotherapy-induced nausea and vomiting (CINV) with high emetogenic potential?

• ALoperamide
• BAprepitant
• CMeclizine
• DDiphenhydramine

Frequently Asked Questions

What is the difference between Leucovorin use in Methotrexate vs. 5-FU?

In Methotrexate therapy, Leucovorin is used as a "rescue" to provide a source of folate for healthy cells after toxic levels of Methotrexate. In 5-FU therapy, Leucovorin is used as a "potentiator" to help 5-FU bind more tightly to thymidylate synthase, increasing its anticancer activity.

Why must Vincristine never be administered intrathecally?

Intrathecal administration of Vincristine is almost always fatal, leading to progressive ascending myeloencephalopathy. It must only be administered intravenously, often prepared in a small volume minibag to prevent accidental spinal injection.

How does Rituximab work in B-cell lymphomas?

Rituximab is a monoclonal antibody that targets the CD20 antigen found on the surface of normal and malignant B-lymphocytes. Once bound, it triggers an immune response that leads to B-cell lysis via complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity.

What is the "hand-foot syndrome" associated with Capecitabine?

Hand-foot syndrome (palmar-plantar erythrodysesthesia) is a skin reaction where small amounts of chemotherapy leak out of capillaries in the palms and soles, causing redness, swelling, and pain. Management includes topical emollients and potentially dose reduction.

When should Rasburicase be used in oncology?

Rasburicase is indicated for the management of uric acid levels in patients with leukemia or lymphoma who are at high risk for Tumor Lysis Syndrome (TLS). It works by converting uric acid into allantoin, which is much more soluble and easily excreted by the kidneys.